Author

E. J. Kay

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Athineos· 2 shared G. Koulouras· 2 shared K. Blyth· 2 shared L. J. Neilson· 2 shared S. Lilla· 2 shared S. Zanivan· 2 shared A. Hedley· 1 shared A. Santi· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Athineos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer-associated fibroblasts produce matrix-bound vesicles that influence endothelial cell function

A. Santi, E. J. Kay, L. J. Neilson, L. McGarry, S. Lilla, M. Mullin, N. R. Paul, F. Fercoq, G. Koulouras, G. Rodriguez-Blanco, D. Athineos, S. Mason, M. Hughes, Y. Kieffer, C. Nixon, , S. Zanivan

CAFs with a myofibroblastic-like phenotype transfer proteins to ECs, including plasma membrane receptors, through matrix-bound EVs.

bioRxiv · Jan 13, 2023 · PreprintCancer Biology

PYCR1-dependent proline synthesis in cancer-associated fibroblasts is required for the deposition of pro-tumorigenic extracellular matrix

E. J. Kay, K. Paterson, C. Riero Domingo, D. Sumpton, H. Daebritz, S. Tardito, C. Boldrini, J. R. Hernandez-Fernaud, D. Athineos, S. Dhayade, E. Stepanova, E. Gjerga, L. J. Neilson, S. Lilla, A. Hedley, , S. Zanivan

This study identifies PYCR1-dependent proline synthesis in cancer-associated fibroblasts as critical for collagen production and tumor progression, suggesting PYCR1 as a therapeutic target to inhibit pro-tumorigenic extracellular matrix deposition.

bioRxiv · May 30, 2020 · PreprintCancer Biology